Inspired to improve the lives of millions of patients and their families living with food allergies worldwide, Aravax is dedicated to revolutionising the treatment of food allergy by developing next-generation, disease-modifying immunotherapies that are safer and more convenient than existing approaches.
Our Proprietary Platform
Although food allergies are on the rise, patients remain underserved with a critical need for better treatments.
Aravax’s next-generation immunotherapies use proprietary peptides designed to precisely retrain the immune system to tolerate specific foods with minimal risk of treatment-induced acute allergic reactions.
Phase 2 Clinical Trials
Aravax’s lead investigational immunotherapy product, PVX108, is the first therapy designed to precisely target the root cause of the disease.
PVX108 delivered positive results in an international Phase 2 clinical trial looking at efficacy and safety.
Latest News
- Aravax Announces Positive Results of Phase 2 Clinical Trial of PVX108, a Novel Immunotherapy for the Treatment of Peanut Allergy 12 November 2026
- Aravax to Communicate Results of its Phase 2 Clinical Trial of PVX108, a Novel immunotherapy for the Treatment of Peanut Allergy, at Major Scientific Meetings in November 2026 5 October 2026
